The Impact of FDAAA On Drug Approvals: Setting the Baseline
By
Michael McCaughan / Email the Author / The RPM Report November 2008, Vol. 4, No. 10
Feature Articles / Word Count: 1758 / Article # 2008500150
Executive Summary
An analysis of the first six months of the new era in drug regulation shows that FDA is enthusiastically and creatively applying its new drug safety tools. Biopharma companies will be watching carefully to see how the metrics of the FDAAA era move over time.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.